Immune-oncology based regimens have shown efficacy in advanced hepatocellular
carcinoma and have been implemented as standard of care as first line therapy. Their …

Hepatocellular carcinoma (HCC) generally develops as a consequence of underlying liver
disease, most commonly viral hepatitis. The development of HCC follows an orderly …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies
worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited …

Hepatocellular carcinoma (HCC), although a very common malignancy, is difficult to
diagnose at a curable stage and treatment is often ineffective. Despite the development of …

BACKGROUND & AIMS: Early treatment has been recommended for hepatocellular
carcinoma (HCC) due to its high cure rate. However, the reported survival benefits of treating …

Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so
therapeutic decisions must account for the degree of underlying liver dysfunction and patient …

Simple Summary Hepatocellular carcinoma (HCC) is the most common type of liver cancer,
accounting for approximately 85–90% of all cases of liver cancer worldwide. The five-year …

Simple Summary Hepatocellular carcinoma (HCC) is the most common primary liver cancer.
High-risk patients should undergo semi-annual surveillance. Management of HCC is …

Global incidence and mortality of hepatocellular carcinoma (HCC) has increased over the
past two decades. Although transplantation and surgical resection offer a chance for cure …

Early diagnosis and aggressive therapy improves outcome in hepatocellular carcinoma
(HCC). Several potentially curative as well as palliative treatment options are available for …